GRCL Stock Recent News

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 02, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the first quarter ended March 31, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, May 15, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will present updated clinical data on GC012F, the Company's FasTCAR-enabled autologous CAR-T cell therapy dual-targeting B-cell maturation antigen (BCMA) and CD19, from ongoing investigator-initiated trials (IIT) in relapsed-refractory multiple myeloma (RRMM) and B-cell non-Hodgkin's lymphoma (B-NHL) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023, in Chicago and online.

Fintel reports that Orbimed Advisors has filed a 13D form with the SEC disclosing ownership of 7.58MM shares of Gracell Biotechnologies Inc.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q4 2022 Earnings Conference Call March 13, 2023 8:00 AM ET Company Participants Kevin Yili Xie - Chief Financial Officer William Wei Cao - Founder, Chairman, and Chief Executive Officer Wendy Li - Chief Medical Officer Conference Call Participants Carly Kenselaar - Citi James Shin - Wells Fargo Justin Zelin - BTIG Emily Bodnar - H.C. Wainwright Operator [Operator Instructions] I would now like to turn the call over to Dr. Kevin Xie, CFO.

SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.

Penny stocks with news to watch this week. The post Penny Stocks To Buy: 4 To Watch With Big News In February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q3 2022 Results Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Kevin Yili Xie - Chief Financial Officer William Wei Cao - Founder, Chairman, and Chief Executive Officer Wendy Li - Chief Medical Officer Conference Call Participants Carly Kenselaar - Citigroup Dev Prasad - Jefferies Joseph Catanzaro - Piper Sandler Justin Zelin - BTIG Suowei Wu - Cantor Fitzgerald James Shin - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. Welcome to Gracell Biotechnologies Third Quarter 2022 Conference Call.

BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the first clinical data of its ongoing Phase 1, investigator-initiated study in China evaluating FasTCAR-enabled GC012F in newly diagnosed, transplant-eligible, high-risk multiple myeloma (NDMM) patients.